While many analysts have been focusing on the growth potential of Regeneron-partnered Dupixent in atopic dermatitis, the French giant has been highlighting the biologic's benefits for asthma with three-year data presented at the ERS meeting.

Sanofi to sell most of its Regeneron stake, with much of it being re-purchased by Regeneron, but both stressed the move would not hurt their long established and very profitable drug-development collaboration.

The 10-year deal aims to use artificial intelligence to map out the cellular biology behind neuroscience and oncology and accelerate drug discovery in another boost to the field.